Acadian Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Acadian Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149K	Buy	26,337 +5,726	+28%	+$46.2K	﹤0.01%	1684
2026 Q1	$188K	Buy	+20,611	New	+$290K	﹤0.01%	1608
2023 Q3	–	Sell	-32	Closed	–	–	1885
2023 Q2	$0	Hold	32	–	–	﹤0.01%	1941
2023 Q1	$0	Sell	32 -3,654	-99%	-$59.1K	﹤0.01%	2002
2022 Q4	$85K	Buy	+3,686	New	+$85.4K	﹤0.01%	1474
2022 Q3	–	Sell	-12,440	Closed	-$239K	–	1881
2022 Q2	$239K	Buy	+12,440	New	+$277K	﹤0.01%	1156

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Acadian Asset Management's LENZ Position: Q2 2026 in Review

Acadian Asset Management increased its LENZ Therapeutics (LENZ) stake by 28% in Q2 2026, buying an estimated $46.2K and bringing the position to 26,337 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #1684.

Acadian Asset Management first reported a position in LENZ in Q2 2022 and has held it in 6 quarters since. The position peaked at $239K in Q2 2022. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Acadian Asset Management held 26,337 shares of LENZ Therapeutics worth $149K as of Q2 2026.
Acadian Asset Management bought 5,726 LENZ Therapeutics shares in Q2 2026, an estimated $46.2K.
LENZ Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1684 holding.
Acadian Asset Management first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 6 quarters since.
Acadian Asset Management's LENZ Therapeutics position peaked at $239K in Q2 2022.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.